Bill Ackman Backs Mark Cuban's Drug Pricing Model: These Healthcare Stocks Could Win—Or Lose

Key takeaways

• Ackman’s endorsement highlights a growing push for transparent drug pricing that could reward insurers embracing lower‑cost models while squeezing PBMs that rely on opaque rebates and spread pricing.
• Cuban’s model adds a 15% markup to wholesale acquisition cost
• Ackman’s endorsement came on September 2, 2026
• Humana partners with Cost‑Plus Drugs via SwiftyRx

What happened

Bill Ackman publicly backed Mark Cuban’s drug‑pricing reform proposals, which aim to let patients buy lower‑priced cash prescriptions without losing insurance benefits, standardize PBM contracts, disclose pricing economics, eliminate gag clauses, and enforce penalties for repeat offenders. Cuban’s Cost‑Plus Drug Company model, which sells drugs at wholesale acquisition cost plus a 15% markup, a pharmacy fee and shipping, exemplifies this approach. Ackman’s endorsement signals that investors…

Why it matters

The proposals threaten the traditional PBM business model that profits from spread pricing and opaque rebates. If insurers adopt lower‑cost, transparent pharmacy solutions, they could reduce drug spending and gain a competitive edge in Medicare Advantage and employer plans. The shift could erode earnings for PBMs and…

Short-term and longer-term

Short-term. Short‑term traders should monitor price action on HUM, CVS, CI, and UNH as the market digests Ackman’s endorsement and the potential for regulatory changes.

Longer-term. Over the next few months, investors should assess which insurers and PBMs are positioning themselves for a transparent pricing future.